Skip to main content
Journal cover image

Bamlanivimab Efficacy in Older and High-BMI Outpatients With COVID-19 Selected for Treatment in a Lottery-Based Allocation Process.

Publication ,  Journal Article
Rubin, EB; Boiarsky, JA; Canha, LA; Giobbie-Hurder, A; Liu, M; Townsend, MJ; Dougan, M
Published in: Open forum infectious diseases
December 2021

Given the challenges associated with timely delivery of monoclonal antibody (mAb) therapy to outpatients with coronavirus disease 2019 (COVID-19) who are most likely to benefit, it is critical to understand the effectiveness of such therapy outside the context of clinical trials.This was a case-control study of 1257 adult outpatients with COVID-19, ≥65 years of age or with body mass index (BMI) ≥35, who were entered into a lottery for mAb therapy.Patients who were called to be offered mAb therapy had a statistically significant 44% reduction in the odds of hospitalization within 30 days of a positive severe acute respiratory syndrome coronavirus 2 test compared with those who were not called (odds ratio [OR], 0.56; 95% CI, 0.36-0.89; P=.01). Patients who actually received bamlanivimab had a statistically significant 68% reduction in the odds of hospitalization compared with those who did not receive bamlanivimab (OR, 0.32; 95% CI, 0.11-0.93; P=.04).This study supports the effectiveness of bamlanivimab in reducing COVID-19-related hospitalizations in patients ≥65 or with BMI ≥35.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Open forum infectious diseases

DOI

EISSN

2328-8957

ISSN

2328-8957

Publication Date

December 2021

Volume

8

Issue

12

Start / End Page

ofab546

Related Subject Headings

  • 3207 Medical microbiology
  • 3202 Clinical sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Rubin, E. B., Boiarsky, J. A., Canha, L. A., Giobbie-Hurder, A., Liu, M., Townsend, M. J., & Dougan, M. (2021). Bamlanivimab Efficacy in Older and High-BMI Outpatients With COVID-19 Selected for Treatment in a Lottery-Based Allocation Process. Open Forum Infectious Diseases, 8(12), ofab546. https://doi.org/10.1093/ofid/ofab546
Rubin, Emily B., Jonathan A. Boiarsky, Lauren A. Canha, Anita Giobbie-Hurder, Mofei Liu, Matthew J. Townsend, and Michael Dougan. “Bamlanivimab Efficacy in Older and High-BMI Outpatients With COVID-19 Selected for Treatment in a Lottery-Based Allocation Process.Open Forum Infectious Diseases 8, no. 12 (December 2021): ofab546. https://doi.org/10.1093/ofid/ofab546.
Rubin EB, Boiarsky JA, Canha LA, Giobbie-Hurder A, Liu M, Townsend MJ, et al. Bamlanivimab Efficacy in Older and High-BMI Outpatients With COVID-19 Selected for Treatment in a Lottery-Based Allocation Process. Open forum infectious diseases. 2021 Dec;8(12):ofab546.
Rubin, Emily B., et al. “Bamlanivimab Efficacy in Older and High-BMI Outpatients With COVID-19 Selected for Treatment in a Lottery-Based Allocation Process.Open Forum Infectious Diseases, vol. 8, no. 12, Dec. 2021, p. ofab546. Epmc, doi:10.1093/ofid/ofab546.
Rubin EB, Boiarsky JA, Canha LA, Giobbie-Hurder A, Liu M, Townsend MJ, Dougan M. Bamlanivimab Efficacy in Older and High-BMI Outpatients With COVID-19 Selected for Treatment in a Lottery-Based Allocation Process. Open forum infectious diseases. 2021 Dec;8(12):ofab546.
Journal cover image

Published In

Open forum infectious diseases

DOI

EISSN

2328-8957

ISSN

2328-8957

Publication Date

December 2021

Volume

8

Issue

12

Start / End Page

ofab546

Related Subject Headings

  • 3207 Medical microbiology
  • 3202 Clinical sciences